AL101

DRUG4 trials

Sponsors

Ayala Pharmaceuticals, Inc,, Alector Inc., M.D. Anderson Cancer Center

Conditions

Adenoid Cystic CarcinomaHealthyMetastatic Adenoid Cystic CarcinomaTriple Negative Breast Cancer

Phase 1

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

CompletedNCT04111666

Alector Inc.Healthy

Start: 2019-12-14End: 2022-06-09Updated: 2022-08-10

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

CompletedNCT04973683

M.D. Anderson Cancer CenterAdenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma

Start: 2021-09-30End: 2026-06-16Updated: 2026-06-24

Phase 2

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

CompletedNCT03691207

Ayala Pharmaceuticals, Inc,Adenoid Cystic Carcinoma

Start: 2018-12-14End: 2022-12-02Updated: 2024-01-31

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

TerminatedNCT04461600

Ayala Pharmaceuticals, Inc,Triple Negative Breast Cancer

Start: 2020-08-14End: 2022-10-11Updated: 2024-02-12

Related Papers

Window of opportunity study of the Notch inhibitor AL101 in Notch1 activated adenoid cystic carcinoma (ACC): Biological effects and biomarker correlates.

Journal of Clinical Oncology2026-05-27

Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer's disease.

2025-07-252 citations

Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch <sup>mut</sup> ).

Journal of Clinical Oncology2022-06-0121 citations

Abstract OT-29-01: Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer

Cancer Research2021-02-152 citations

AL101 mediated tumor inhibition in notch-altered TNBC PDX models.

Journal of Clinical Oncology2019-05-2017 citations

ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notch<sup>act mut</sup>).

Journal of Clinical Oncology2019-05-209 citations